[1] He M, Wang C, Zhang L. Potential therapeutic role and mechanism of mesencephalic astrocyte-derived neurotrophic factor in metabolic disease. Diabetes Weight Manag J, 2020; 1, 1−8.
[2] Yang S, Li SH, Li XJ. MANF: a new player in the control of energy homeostasis, and beyond. Front Physio, 2018; 9, 1725.
[3] He M, Wang C, Long XH, et al. Mesencephalic astrocyte-derived neurotrophic factor ameliorates steatosis in HepG2 cells by regulating hepatic lipid metabolism. World J Gastroenterol, 2020; 26, 1029−41. doi:  10.3748/wjg.v26.i10.1029
[4] Lindahl M, Danilova T, Palm E, et al. MANF is indispensable for the proliferation and survival of pancreatic β cells. Cell Rep, 2014; 7, 366−75. doi:  10.1016/j.celrep.2014.03.023
[5] Wu T, Zhang F, Yang Q, et al. Circulating mesencephalic astrocyte-derived neurotrophic factor is increased in newly diagnosed prediabetic and diabetic patients, and is associated with insulin resistance. Endocr J, 2017; 64, 403−10. doi:  10.1507/endocrj.EJ16-0472
[6] Galli E, Härkönen T, Sainio MT, et al. Increased circulating concentrations of mesencephalic astrocyte-derived neurotrophic factor in children with type 1 diabetes. Sci Rep, 2016; 6, 29058. doi:  10.1038/srep29058
[7] Gómez-Ambrosi J, Catalán V, Ramírez B, et al. Plasma osteopontin levels and expression in adipose tissue are increased in obesity. J Clin Endocrinol Metab, 2007; 92, 3719−27. doi:  10.1210/jc.2007-0349
[8] Yamaguchi H, Igarashi M, Hirata A, et al. Progression of diabetic nephropathy enhances the plasma osteopontin level in type 2 diabetic patients. Endocr J, 2004; 51, 499−504. doi:  10.1507/endocrj.51.499
[9] Carbone F, Adami G, Liberale L, et al. Serum levels of osteopontin predict diabetes remission after bariatric surgery. Diabetes Metab, 2019; 45, 356−62. doi:  10.1016/j.diabet.2018.09.007
[10] Kiefer FW, Neschen S, Pfau B, et al. Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice. Diabetologia, 2011; 54, 2132−42. doi:  10.1007/s00125-011-2170-0